CD8A and neoplasm: A recent investigation has demonstrated that OMVs that are adorned with Epidermal Growth Factor Receptor Variant III (EGFR vIII) and B16-M30 have elicited elevated levels of anti-EGFR vIII antibody titers, M30-specific T cells, and the infiltration of CD4+ and CD8+ T cells at the tumor site50.